| 000 | 01771 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513231545.0 | ||
| 264 | 0 | _c20010201 | |
| 008 | 200102s 0 0 eng d | ||
| 022 | _a0077-8923 | ||
| 024 | 7 |
_a10.1111/j.1749-6632.2000.tb07038.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGupta, E | |
| 245 | 0 | 0 |
_aPharmacokinetics of orally administered camptothecins. _h[electronic resource] |
| 260 |
_bAnnals of the New York Academy of Sciences _c2000 |
||
| 300 |
_a195-204 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnion Transport Proteins |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xpharmacokinetics |
| 650 | 0 | 4 |
_aBiological Transport, Active _xdrug effects |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aCaco-2 Cells _xmetabolism |
| 650 | 0 | 4 |
_aCamptothecin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aCarrier Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCell Membrane Permeability |
| 650 | 0 | 4 |
_aColonic Neoplasms _xmetabolism |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydrolysis |
| 650 | 0 | 4 |
_aIntestinal Absorption _xdrug effects |
| 650 | 0 | 4 |
_aIntestinal Mucosa _xmetabolism |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 |
_aLiver Neoplasms _xmetabolism |
| 650 | 0 | 4 |
_aProbenecid _xpharmacology |
| 650 | 0 | 4 |
_aProdrugs _xpharmacokinetics |
| 650 | 0 | 4 |
_aRectal Neoplasms _xmetabolism |
| 700 | 1 | _aVyas, V | |
| 700 | 1 | _aAhmed, F | |
| 700 | 1 | _aSinko, P | |
| 700 | 1 | _aCook, T | |
| 700 | 1 | _aRubin, E | |
| 773 | 0 |
_tAnnals of the New York Academy of Sciences _gvol. 922 _gp. 195-204 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1749-6632.2000.tb07038.x _zAvailable from publisher's website |
| 999 |
_c11132078 _d11132078 |
||